Core Research Group Pty Ltd

Milton, Queensland 4064

3 studies enrolling now · 12 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Cardiovascular Disease, Coronary Heart Disease (CHD), Diabetic Cardiomyopathies, Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Hyperlipidemia, Influenza, Obesity, Overweight

Studies at this site

• OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — Recruiting now
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke — Completed
• A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza — Running, not enrolling
• Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study — Completed
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Running, not enrolling
• A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) — Completed
• Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy — Running, not enrolling
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events — Completed